Talphera (NASDAQ:TLPH) Stock Rating Upgraded by Wall Street Zen

Talphera (NASDAQ:TLPH) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

A number of other analysts have also recently commented on the stock. Westpark Capital started coverage on shares of Talphera in a report on Thursday, April 30th. They set a “buy” rating and a $3.00 target price for the company. HC Wainwright started coverage on shares of Talphera in a research note on Friday, June 5th. They issued a “buy” rating and a $3.00 price objective for the company. Zacks Research upgraded shares of Talphera to a “hold” rating in a report on Monday, June 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Talphera has a consensus rating of “Hold” and a consensus target price of $3.00.

Talphera Price Performance

TLPH opened at $1.43 on Friday. The stock has a 50-day moving average price of $1.14 and a 200-day moving average price of $0.95. The firm has a market cap of $74.22 million, a PE ratio of -4.61 and a beta of 0.69. Talphera has a 1 year low of $0.39 and a 1 year high of $1.57.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. As a group, sell-side analysts anticipate that Talphera will post -0.26 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Group One Trading LLC boosted its stake in shares of Talphera by 3,224.0% during the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after purchasing an additional 29,500 shares during the period. Virtu Financial LLC purchased a new position in Talphera in the 3rd quarter worth about $29,000. Mariner LLC lifted its holdings in Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after buying an additional 33,000 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Talphera in the 4th quarter valued at about $42,000. Finally, Dauntless Investment Group LLC purchased a new stake in Talphera in the 3rd quarter valued at about $89,000. 37.67% of the stock is owned by hedge funds and other institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.